Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Prostate Biopsy Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy AHS-G2007

    Prostate Biopsy Specimen Analysis

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy AHS-G2007 alerts

    Get alerted when Policy AHS-G2007 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage for pathological examination of prostate biopsy tissue used to diagnose, stage, or manage suspected prostate cancer, including biopsies following abnormal PSA results, suspicious examination or imaging findings, or persistent suspicion after a negative biopsy.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyProstate Biopsy Specimen Analysis
    Policy CodePolicy AHS-G2007
    Change TypeAdministrative and clarifying update
    Effective DateFeb 1, 2026
    Next Review DateNot specified
    Key ActionFor an initially covered biopsy, document the qualifying indication, use 12-core extended sampling, and package specimens as one vial per sextant with no more than two cores per vial.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was reviewed and updated with revisions to the background, guidelines and recommendations, and evidence-based scientific references.

    The policy clarified that each vial, regardless of the number of enclosed biopsy cores, is considered a single specimen for billing purposes.

    The policy previously added a New Mexico Medicaid link to the applicable state and federal regulations section.

    12 coresInitial biopsy sampling requirement
    1 vial/sextantSpecimen configuration
    Not coveredSaturation biopsy coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsRepeat biopsy or MRI interval
    2Applicable procedure codes

    Coverage Criteria

    Initial diagnostic biopsy

    Covered when all of the following are met:

    Initial diagnosis of prostate cancer

    • Qualifying clinical suspicion

      • The biopsy follows an abnormal PSA result.
      • The biopsy follows a palpable nodule on digital rectal examination.
      • The biopsy follows suspicious radiologic findings.
    • Biopsy sampling method: The prostate biopsy involves 12-core extended sampling.12 cores

      See the specimen configuration requirement: one vial per sextant and no more than two core samples per vial.

    title||||Initial diagnostic biopsy
    ref||||b0_0
    title||Initial diagnostic biopsy

    Follow-up biopsy after negative initial biopsy

    Covered when all of the following are met:

    Follow-up biopsy after negative initial biopsy: Clinical suspicion of prostate cancer remains after an initial biopsy was negative for prostate cancer, and the follow-up biopsy is not a prostate saturation biopsy.

    Pathological examination of tissue from the follow-up prostate biopsy meets coverage criteria.

    Saturation biopsy

    Does not meet coverage criteria:

    Saturation biopsy analysis: The tissue was obtained from a prostate saturation biopsy and analysis is requested for the diagnosis, staging, or management of prostate cancer.

    The policy states that this service does not meet coverage criteria.

    MRI-directed biopsy decision

    ESMO recommendation for biopsy after multiparametric MRI:

    • Positive multiparametric MRI: Perform a targeted systematic or non-systematic biopsy.PI-RADS ≥3
    • Negative multiparametric MRI with low clinical suspicion: Biopsy can be omitted.PI-RADS ≤2

      Omission applies when clinical suspicion of cancer is low.

    Biopsy indication for PSA elevation

    For asymptomatic individuals with a PSA level between 3 and 20 ng/mL and a normal DRE, use one of the following tools to determine biopsy indication:

    Biopsy-indication assessment

    • Assessment tool

      • Use magnetic resonance imaging of the prostate.
      • Use a risk calculator that is correctly calibrated to the population prevalence.
      • Use an additional serum or urine biomarker test.

    Preferred biopsy sampling approach

    NCCN approach to initial and repeat biopsy:

    Preferred biopsy approach: When MRI-targeting capabilities are available, combine systematic and targeted sampling, particularly for the initial biopsy, using an extended pattern of at least 12 cores.At least 12 cores

    For persistent suspicion after a negative biopsy, MRI followed by an appropriate targeted biopsy technique may be considered. Routine saturation biopsy is not recommended for all individuals with previous negative biopsies.

    Pathological examination of tissue obtained from a prostate saturation biopsy is excluded when requested for the diagnosis, staging, or management of prostate cancer.

    The NCCN does not recommend a saturation biopsy strategy for all individuals with previous negative biopsies. For persistent clinical suspicion after a negative biopsy, NCCN supports consideration of multiparametric MRI followed by an appropriately targeted biopsy technique.

    Prostate saturation biopsy specimen analysis does not meet coverage criteria because published scientific literature confirming that the test is required and beneficial for diagnosis and treatment is lacking.

    Coding and Clinical Thresholds

    Applicable CPT/HCPCS Procedure Codesmixed
    88305Level IV - Surgical pathology, gross and microscopic examination.
    G0416Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method
    Positive multiparametric MRI
    Positive MRIPI-RADS ≥3
    Negative multiparametric MRI
    Negative MRIPI-RADS ≤2
    PSA range for biopsy-indication tools
    PSA range3–20 ng/mL with normal DRE

    Provider Documentation and Billing Actions

    Documentation Required

    Document the initial biopsy and specimen configuration

    For an initially covered biopsy, document the qualifying indication—abnormal PSA result, palpable nodule on digital rectal examination, or suspicious radiologic findings—and confirm that the biopsy uses 12-core extended sampling. Record one vial per sextant, with no more than two core samples per vial; each vial is considered a single specimen for billing regardless of the number of enclosed cores.

    • Qualifying indication: abnormal PSA, palpable nodule on digital rectal examination, or suspicious radiologic findings.
    • Sampling: 12-core extended biopsy.
    • Specimen configuration: one vial per sextant; no more than two cores per vial.
    • Billing: each vial is one specimen, regardless of the number of cores enclosed.
    Denial Risk

    Avoid non-covered saturation biopsy analysis

    Clinical Background

    Prostate cancer ranges from microscopic, well-differentiated disease that may never become clinically significant to aggressive, high-grade malignancy. An abnormal PSA, a palpable nodule or other abnormal digital rectal examination finding, or suspicious imaging may indicate the need for biopsy. Extended sampling improves the opportunity to detect cancer compared with limited sampling, making biopsy technique and specimen assessment important to diagnosis and subsequent management.

    Definitions and Abbreviations

    ACR
    ACRAmerican College of Radiology
    ACS
    ACSAmerican Cancer Society
    ASCO
    ASCOAmerican Society of Clinical Oncology
    ASTRO
    ASTROAmerican Society for Radiation Oncology

    Covered Services and Indications

    Initial 12-core extended prostate biopsy pathology

    Covered for initial diagnosis when all of the following are met:

    • Qualifying clinical indication

      • The biopsy follows an abnormal PSA result.
      • The biopsy follows a palpable nodule on digital rectal examination.
      • The biopsy follows suspicious radiologic findings.
    • Sampling and specimen configuration

      • The prostate biopsy uses 12-core extended sampling.

    Frequency and Monitoring Limits

    Repeat prostate biopsy and/or multiparametric MRI
    Repeat biopsy or mpMRIGenerally no more often than every 12 months unless clinically indicated, such as a PSA increase
    Prostate biopsy during active surveillance
    Active surveillance biopsyEvery two to five years for most patients as part of monitoring

    Not Covered Services

    Not covered: pathological examination of tissue obtained from a prostate saturation biopsy for the diagnosis, staging, or management of prostate cancer.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyProstate Biopsy Specimen Analysis
    Policy CodePolicy AHS-G2007
    Change TypeAdministrative and clarifying update
    Effective DateFeb 1, 2026
    Next Review DateNot specified
    Key ActionFor an initially covered biopsy, document the qualifying indication, use 12-core extended sampling, and package specimens as one vial per sextant with no more than two cores per vial.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Billing ActionsClinical BackgroundDefinitions and AbbreviationsCovered Services and IndicationsFrequency and Monitoring LimitsNot Covered Services

    Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria when requested for the diagnosis, staging, or management of prostate cancer. Submitting saturation-biopsy analysis for these purposes creates a coverage denial risk.

    • Saturation biopsy specimen analysis is not covered for diagnosis, staging, or management of prostate cancer.
    • The policy cites a lack of published scientific literature confirming that the test is required and beneficial for diagnosis and treatment.
    Step Therapy

    Use MRI-directed targeted biopsy after a negative biopsy

    Do not use routine saturation biopsy for all patients with previous negative biopsies. When clinical suspicion persists, use MRI followed by an appropriately targeted biopsy technique based on the MRI results.

    • A negative biopsy does not preclude a later prostate cancer diagnosis if clinical suspicion persists.
    • For persistently elevated-risk patients, consider MRI followed by targeted biopsy.
    • NCCN does not recommend a saturation biopsy strategy for all individuals with previous negative biopsies.
    AUA
    AUAAmerican Urological Association
    CC
    CCCubic centimeters
    CS
    CSClinically significant
    csPCa
    csPCaAll clinically significant cases of prostate cancer
    DRE
    DREDigital rectal examination
    EAU
    EAUEuropean Association of Urology
    ESMO
    ESMOEuropean Society for Medical Oncology
    FBx
    FBxFusion biopsy
    FDA
    FDAFood and Drug Administration
    GG2
    GG2Grade 2 or greater
    LDT
    LDTLaboratory-developed test
    MicroUS
    MicroUSMicro-ultrasound
    mpMRI
    mpMRIMultiparametric magnetic resonance imaging
    MRI
    MRIMagnetic resonance imaging
    NCCN
    NCCNNational Comprehensive Cancer Network
    NPV
    NPVNegative predictive value
    NYU
    NYUNew York University
    PI-RADS
    PI-RADSProstate Imaging Reporting and Data System
    PROMIS
    PROMISProstate magnetic resonance imaging study
    PSA
    PSAProstate-specific antigen
    RP
    RPRadical prostatectomy
    SBx
    SBxTransrectal ultrasound biopsy
    SUO
    SUOSociety of Urologic Oncology
    TPM
    TPMTemplate prostate mapping
    TRUS
    TRUSTransrectal ultrasound
    UCLA
    UCLAUniversity of California, Los Angeles
    US
    USUltrasound
    USPSTF
    USPSTFUnited States Preventive Services Task Force
    CLIA '88
    CLIA '88Clinical Laboratory Improvement Amendments of 1988
    CMS
    CMSCenters for Medicare and Medicaid
    PPV
    PPVPositive predictive value
    Positive or negative multiparametric MRI
    Positive MRIPI-RADS score 3 or higher
    Negative MRIPI-RADS score 2 or lower
    Laboratory-developed test (LDT)
    Development and validationDeveloped and validated in-house by laboratories
    Performance settingPerformed in-house by laboratories
    Regulatory classificationRegulated by CMS as high-complexity tests under CLIA '88
    12 cores
  1. Specimens are submitted as one vial per sextant.1 vial per sextant
  2. No more than two core samples are placed in each vial.≤2 cores per vial

    Each vial is considered a single specimen for billing, regardless of the number of enclosed biopsy cores.

  3. Follow-up prostate biopsy pathology

    Covered when all of the following are met:

    • Clinical suspicion of prostate cancer remains after an initial biopsy was negative for prostate cancer.
    • The follow-up procedure is not a prostate saturation biopsy.

      Follow-up saturation biopsy is excluded.

    Surgical pathology examination

    Covered for surgical pathology examination of prostate needle-biopsy specimens:

    Applicable pathology service

    • Level IV surgical pathology, gross and microscopic examination.
    • Surgical pathology, gross and microscopic examinations, for prostate needle biopsy by any method.